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Abstract
The rise of prostate cancer diagnoses in the early 1990's due to better detection
techniques and the recent advances in the clinical management of the disease have
required better technologies for detection and monitoring disease status.
The focus of my research at the Bioinstrumentation Laboratory was to design, fabricate
and test an instrument for the preparation of excised frozen tissue from prostate cancer
tumors in patients for conformal mapping of the sampling points to the local tissue
geometry. This instrument was designed specifically for use on frozen samples that have
been archived and the work involves solving issues inherent in extracting information
from frozen tissue without denaturing DNA, RNA and proteins. Isolation of the nucleic
acids from the bulk tissue and real time PCR amplification of a 152 bp segment of the
androgen receptor was used to verify that the tissue was extracted successfully using the
device.
It is the intention of this work and others like it that quick and efficient mapping
technologies will come into widespread use in predicting tumor size and growth rates
thereby improving cancer patient diagnosis and treatment.
Thesis Supervisor: Ian W. Hunter
Title: Hatsopoulos Professor of Mechanical Engineering and Professor of BioEngineering
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Chapter 1 Introduction
1.1 Tissue Sampling Device
Prostate cancer accounts for 10% of all cancer deaths in males and is second only
to lung cancer in taking lives. The projected number of incidences will approach a quarter
of a million in 2005 with approximately 30,000 deaths in America alone'. Although
prostate cancer is the leading diagnosed cancer, in many cases, the cancer is latent for a
long period resulting in very low overall mortality rates. Treatments vary widely
depending on the growth rate of the cancer and include everything from watchful waiting,
chemotherapy or immunotherapy to radical prostatectomy.
In order to lower mortality rates, curative measures appear to provide the greatest chance
of survival, where the tumor is found and treated while it is still localized to the prostate.
In which case, radical prostatectomy is the best management option available to prostate
cancer patients. If more accurate information is acquired about the tumor leading to better
local control there are good chances for a long term cure. In an effort to obtain as much
tumor information as possible, molecular profiling is used to assess changes in mRNA
and protein expression that are associated with specific cancers. Molecular profiling
requires the use of multiple biomarkers. In order to realize the full potential of this
approach, techniques must be developed that allow profiling of specimens in a clinical
environment.
Naitoh J, Zeiner R, Dekernion J. Diagnosis and Treatment of Prostate Cancer., University of California, Los Angeles, School of
Medicine, Los Angeles, California
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The heterogeneity inherent in tissue specimens can complicate profiling. In order
to obtain the most information from biomarkers, it is essential that techniques be
developed that maintain spatial context. Gaston et a12 have developed a rather novel
approach to this problem. Tissue prints provide a two dimensional anatomical image of
the tissue surface. Biological molecules comprising the tissue can be visualized using
protein and RNA and DNA detection techniques. In addition, the proteins comprising the
tissue can be further imaged by print-phoresis, a technique that involves the separation of
proteins in a tissue strip by polyacrylamide gel electrophoresis (PAGE).
Tissue printing allows the rapid acquisition of a copy of the surface of the tissue
specimen without altering/damaging the specimen prior to its being evaluated by the
pathologist. More commonly, tissue specimens/biopsies are prepared for sectioning.
While paraffin embedded sections provide more accurate morphology, cryosections
provide a more accurate reflection of the distribution of molecules. In either case, the
preparation of sections and application of ensuing detection methodologies is laborious.
The aim of this thesis was to develop a technology that could rapidly extract
biomolecules from frozen tissue sections for profiling while maintaining spatial context.
The following chapters will detail the major device requirements, the design process, the
characterization of the instrument, and preliminary results obtained when the device was
used to process tissue from sections of guinea pig lung.
2 Gaston S., Soares M., Siddiqui M., Vu D., Lee J., Golder D., Brice M., Shih J., Upton M., Perides G., Baptista J., Lavin P., Bloch
B., Genega E., Rubin M. and Lenkinski R. Tissue-Print and Print-Phoresis as Platform Technologies for the Molecular Analysis of
human Surgical Specimens: Mapping Tumor Invasion of the Prostate Capsule. Nature Medicine 11(1): 95-101, 2005.
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Chapter 2 Background
2.1 Prostate Cancer
Prostate cancer (PCa) is the second leading cancer resulting in death in the US
today. Studies over the years have linked the incidence of the disease with family history,
with 5-10% of men developing clinical prostate cancer if there was strong familial
predisposition. High fat diets are also associated with high risk of developing the disease
evidenced by higher rates in North America and Europe and lower rates in Asia. Another
factor linked to incidence is race as African men are diagnosed with the disease more
frequently than Caucasian or Asian men.
In the early 1990's the monitoring of Prostate Specific Antigen (PSA), a protein
produced by the prostate along with Digital Rectal Examinations (DRE) became the gold
standard for detecting and diagnosing prostate cancer. Although false negatives and false
positives can occur with either form of testing, if an abnormality occurs during a PSA test
the alternate form of testing can confirm or deny tumor presence. Improved evaluation
resulted in a significant increase in PCa diagnosis. Commensurate with this was a 2.5%
drop in the number of men succumbing to the disease in the proceeding years: 1992 -
1996'. Today, approximately 30% of men diagnosed with PCa develop the clinical cancer
which is fatal. As the diagnosis of PCa becomes more and more efficient, the key to
reducing mortality rates is the treatment of incidences that are likely to become clinical.
3 Theodorescu D, Mellon P. Prostate Cancer: Biology, Diagnosis, Pathology, Staging, and Natural History
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PCa treatments vary with patient age, life expectancy, possible side effects (long
term or short term), expected cancer recurrence, and financial and emotional costs to the
patient. In the case of younger patients, with a long life expectancy (more than 10 years)
radical prostatectomy appears to be the best option. For older patients, radiotherapy may
be a better option than surgery, as the chances of curing are about the same as surgery,
but with fewer side effects. While the chances of recurrence increase, both the financial
and physical cost to an older patient outweigh the risk.
For older patients with a short life expectancy, waiting and observing the tumor
maybe be the best form of treatment as tumors grow so slowly that it might benefit the
patient to take no action. Surprisingly, autopsies performed on older men usually turn up
prostate cancer even though it was not the cause of death.
It is the hope that tissue sampling techniques used in combination with molecular
profiling will provide a more rapid means of obtaining critical information required to
make an informed treatment decision.
2.2 Androgen and The Androgen Receptor
2.2.1 Function
Androgens are hormones associated with male reproductive organs; indeed, it is
the hormone androgen that in the human embryo causes the development and
differentiation of these sexual reproductive organs in males. It is also responsible for the
growth of the prostate gland and the start of spermatogenesis 4 in these organs during male
pubescence. In addition to vital roles in reproductive organ development, androgens also
mediate physiological responses in a range of other tissues and organs such as the skin,
cardiac muscle, skeletal muscle and the central nervous system5 . In the Figure 1 below,
the prostate gland can be seen with respect to the reproductive organ positioning.
4 Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Front Biosci, I:d59-71, 1996.
5 Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocrine Review, 8:1-28, 1987.
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Figure 1. The male reproductive organs (copied from Cancer Links USA).
Androgens help to maintain normal function and structure of the prostate. They
exert this effect by binding to the androgen receptor (AR), a ligand dependent
transcription factor6 . When activated, the androgen receptor regulates tissue specific
expression of target genes7 . The AR is expressed in all tissue and organs with the
exception of spleen and bone marrow. In the absence of ligand, the AR is distributed
over both the nucleus and cytoplasm. When ligand is bound, the activated ARs form
homodimers, enter the nucleus, and activate DNA transcription.
That androgens play a role in the development of prostate cancer is inferred by the
fact that androgen ablation therapy inhibits tumor growth in the initial stage of the
development of the cancer. As the tumor begins to proliferate rapidly, it reaches a
hormone independent state and androgen, or lack there of, no longer promotes nor
6 Nelson K. and White J. Androgen Receptor CAG Repeats and Prostate Cancer, American Journal of Epidemiology.
7 Rahman M, Miyamoto H, Chawnshang C. Androgen Receptor Coregulators in Prostate Cancer. Clinical Cancer Research 10 :2208-
2219, 2004.
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prohibits its development. Secondly dogs and males castrated before puberty do not
develop prostate cancer. In a study done by Rahman et al.7 to determine AR effect on
prostate cancer progression, it was found that even androgen independent prostate cancer
tumor growth may still depend on a functional AR signaling pathway. They suggest that
there are three possible scenarios by which AR can continue to promote tumor cell
proliferation; the first of which is that during androgen ablation therapy, an over-
expression of 5a-reductase and AR co-activators help tumor cells to rapidly convert the
small amount of available androgens to dihydrotestosterone (DHT) and the co-activators
may render AR more sensitive to usually weak adrenal androgens. Another suggestion is
that AR amplifies itself, leading to enhanced ligand occupied AR. Lastly, AR gene
mutations can allow the cancerous prostate cells to circumvent the androgen requirement.
2.2.2 The AR as a Tumor Marker
In the preceding section, a good case was made for the presence of AR in tumor
cells even at the androgen independent stage of growth. Zhou et al8, in development of a
micro-scaled yeast based bioassay for monitoring androgen receptors in sera and tissue,
found that AR bioassay serum androgen was positively correlated to the mass of the
tumor. The study used androgen bioassays as biomarkers for soy based dietary
interventions for prostate cancer. Other sera observed, for instance, testosterone serum
and DHT serum did not show correlation in either case.
8 Zhou J-R., Zhong Y., Yu L., Gaston SM., Nassr RL., Franke AA., and Blackburn GL. (2002) Inhibition of Orthotopic Growth and
Metastasis of Human Prostate LNCaP Tumors in Mice by Bioactive Soybean Components. The Prostate 53: 143-153
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2.3 Existing Tissue Sampling Techniques
2.3.1 Tissue-Print and Print-Phoresis Technologies for Fresh Tissue
Tissue-Print and Print-Phoresis techniques were developed for potential use in
profiling biopsies and surgical specimens in clinical setting. The tissue print technique
involves the transfer of cells and extracellular matrix components from the surface of the
specimen (either exterior or interior) to a nitrocellulose membrane. The nitrocellulose
membranes used in this procedure have a binding capacity of one gram protein per square
meter.
Figure 2. Panels showing (a) the prostate (b) the prostate with the nitrocellulose membrane and (c)
the tissue print of the prostate exterior (copied from Gaston et al).
The tissue prints can then be used for immunoblot analysis using antibodies to
specific biomarkers. Prints can also be used for nucleic acid based detection. DNA or
RNA is isolated from the nitrocellulose using standard methodologies and amplified
using the real time polymerase chain reaction (rt-PCR) or reverse transcribed rt PCR (q
rt-PCR) respectively. Expression of the biomarker of interest, as determined by the PCR
product, can then be correlated with replicate prints used for immunohistochemistry
(IHC).
Print-Phoresis was developed to obtain a better visualization of the number of
markers on each print that can be obtained using direct immunoblotting. Gaston et al
developed a modified protein electrophoresis technique that takes a 2 mm wide strip of
the tissue print, loads each strip onto a preparative polyacrylamide gel, and separates the
proteins present in the strip by electrophoresis as shown schematically in Figure 3.
18
4-" &
A r#0 mrW
Each s&O~ Awm on a gradho PAGE gel
Weswen bw (
zyiqgwm af mbys
Figure 3. A schematic of the print phoresis process (copied from Gaston et al).
This process recovers 70-80% of the protein markers from the strip of
nitrocellulose and can spatially map the markers on the tissue surface. This spatial
representation can then be compared with characteristics of the tissues in corresponding
areas.
2.3.2 TMAs: Kononen and Hoos Methods
The first major advance towards a high throughput method of tissue
microarraying 9'1 0 (TMA) of samples was accomplished by Juha Kononen et al. Samples
from frozen tissue archives or freshly fixed paraffin blocks are obtained by punching into
the solid block with a 0.6 mm hollow cylinder as shown in Figure 4. The sample is then
transferred to a recipient paraffin block using a solid stainless steel stylet.
9 Koneonen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., Torhorst J., Mihatsch M., Sauter G. and
Kallioniemi 0. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine 4: 844-847 (1999)
10Kallioniemi 0., Wagner U., Kononen J. and Sauter G. Tissue microarrays for high-throughput molecular profiling of cancer. Human
Molecular Genetics. 10: 657-662 (2001)
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Figure 4. Kononen tissue microarray method (copied from Kononen et al).
The recipient block is sectioned to produce multiple samples with identical
coordinates on which DNA detection, mRNA in situ hybridization, and IHC can be
carried out for all the tissue targets in the array. Using a microtome, sections as thin as 4
to 8 tm are attainable, amounting to some 200 per recipient block. An adhesive-coated
tape is used during the sectioning to transfer the precise locations of the tissue spots in the
array to the microscope slides for analysis.
--- ---- -- ---
Figure 5. A 5 Am section of the tumor array recipient block showing the 0.6mm diameter cores with
0.8 mm spacing (copied from Kononen et al).
The main benefits of this sampling system are the preservation of tissue and the
sheer volume of tissue that can be analyzed simultaneously. Preliminary results showed
that for a series of 611 breast cancers, the results from use of TMAs proved to be equally
good or better than analysis of individual large sections. However, the results obtained
reflected careful selection of regions of interest within a morphologically heterogeneous
tumor which substantially increases the representativity of the results.
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Hoos and Cordon-Cardo"l produced similar results from their validation 2 of
TMAs; however, they found that in the analysis of frozen tissues with the 0.6 mm core
arrays, the results were limited with respect to RNA targets and certain proteins. They
proceeded to augment this design by producing a recipient block of optimal cutting
temperature (OCT) compound with core diameters of 3.0 mm. This recipient block
contained only 48 holes, and frozen tissue was transferred to them using a plate of ejector
pins similar to the Kononen method. The device is shown in Figure 6.
A
Figure 6. A - Cryoapparatus ejector plate B - 3.0mm core needle (top) and ejector pin (bottom)
(copied from Hoos et al).
Using these larger diameter cores operators need to pay less attention to tissue
morphology during the selection process and may require as few as one or two biopsies
to represent the entire specimen. Although the throughput is lower than the previous
TMAs, the cryoapparatus produces more accurate results. Future work includes
optimizing tissue handling and array quality.
2.3.3 Validation of TMAs for Profiling
There are many concerns about the use of 0.6 mm or even 3.0 mm diameter cores
to represent the morphology of the entire tissue or tumor under analysis. Firstly, the type
of tissue to be analyzed must be considered. Hoos and Cardon-Cardol make a very
strong argument for not applying TMAs in analysis of every type of tumorous tissue. In
colorectal cancer, where target areas are small and well defined, a core biopsy can miss
" Hoos A. And Cordon-Cardo C. Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations.
Laboratory Investigation, 81:1331-1338,2001.
12 Hoos A., Urist M., Stojadinovic A., Mastorides S., Dudas M., Leung D., Kuo D., Brennan M., Lewis J. and Cordon-Cardo C.
validation of Tissue Microarrays of Immunohistochemical Profiling of Cancer Specimens Using the Example of Human Fibroblastic
Tumors. American Journal of Pathtology, 158: 1245-1251, 2001.
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the tumor cells and instead sample the stromal areas between the glandular structures of
the tumor that can be very large. In contrast, thyroid tumors contain relatively large
nodules with a concentration of cancer cells that are large enough that they will definitely
be sampled by most sampling instruments. An additional consideration in sampling is
tissue heterogeneity.
Another validation of TMAs by Camp, Charette and Rimm13 focused on the
analysis of protein expression patterns in invasive breast carcinoma. By looking at three
different antigens and a range of tissue dating back to 1932, they validated a 95%
representation with the use of the TMAs if two or more of the sampled disks were
readable. They put to rest fears that archived tissue would not be suitable for IHC
analysis.
The results of these studies validate the use of TMAs for adequately representing
biomarkers for breast cancer tumors. This thesis proposes a method which uses the entire
cross sectional area of samples, when mapping tumor markers in prostate cancer
specimen instead of selecting specific positions to sample.
2.4 Tissue Sampling Device Prototype
2.4.1 Major Differences
The tissue sampling device discussed in this thesis is designed to sample frozen
tissue sections. It differs from the previously discussed technologies in two important
respects. Firstly, the entire tissue specimen is used during the analysis. Current
microarray technology reduces the amount of tissue and tumor analyzed from the whole
tissue section to a cylinder or disk between 0.6 and 3.0 mm in diameter. These assumed
local homogeneity of tissue which is not always the case. There are however, many
advantages, especially higher throughput and conservation of tissue among the
forerunners. Another factor that led to the use of the entire section was the ease in
designing a grid like structure and relative lack of operator bias/inefficiency. Cores do not
13 Camp R, Charette L and Rimm D. Validation of Tissue Microarray Technology in Breast Carcinoma Laboratory Investigation 80:
1943-1949, 2000.
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have to be "selected" by the operator, so less time is spent on preparation or pre-
examination of the tissue to be sampled making this process more efficient than any of
the core samplers.
The second difference also involved the mechanical manipulation of the tissue
section. This design eliminates the transfer of a 4 pm section to a microscope slide to be
analyzed. Instead, "cores" or sampled tissue plugs are pushed directly into a well plate
containing extraction buffer. The well plate maintains the coordinates and orientation of
the original specimen. With the use of a 384 well plate, moderate throughput is achieved
for a device that analyzes entire specimen sections. The interest, ultimately, is in the
spatial mapping of the RNA expression using q rt-PCR , retaining or producing multiple
samples of the same specimen for IHC and DNA ISH are not a priority with this process.
Although none of the above techniques give the same advantage as the tissue print
technology, this device provides a means by which comparable data could be obtained
from already sectioned tissue.
2.4.2 Expected Results from q rt-PCR or rt-PCR
Q rt-PCR or rt-PCR will be used to demonstrate that the tissue extracted from the
tissue sampling device being fabricated for this project can be used for molecular
profiling. A schematic of the various steps involved in a rt-PCR are outlined below.
Polyadenylated mRNA isolated from individual grids within the larger grid is reversed
transcribed using a an oligo-dT primer, dNTPs, and reverse transcriptase to create the
first strand cDNA as shown in Figure 7.
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Reverse Transcriptase
CA C C
C C C
mRNA
cDNA
Figure 7. The first strand of cDNA is synthesized using reverse transcriptase (copied from
Contemporary Topics by the Ameircan Association for Laboratory Aniumal Science).
Treatment with RNase H removes the starting template strand of mRNA leaving
only the single stranded cDNA.
mRNA RNAse H
C CC
cDNA
Figure 8. Denaturation of the cDNA takes place as the mRNA is removed (copied from
Contemporary Topics by the Ameircan Association for Laboratory Aniumal Science).
Similar to the PCR process, an oligonucleotide primer anneals to the single stranded
cDNA and in the presence of dNTPs and DNA polymerase extends it to yield double
stranded cDNA (ds cDNA) as in Figure 9.
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Figure 9. Primer produces the first copy of double stranded cDNA for PCR (copied from
Contemporary Topics by the Ameircan Association for Laboratory Aniumal Science).
Primers specific to the biomarker of interest are then used to amplify the ds cDNA
using the PCR (see Figure 10).
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STEP 1 : denaturation of the cDNA strand at
94 C for 60 s.
STEP 2 : annealing of forward and reverse
primers at 54' C for 45 s.
STEP 3 : extension of the single strands to
produce double stranded DNA at 72 0 C for 120 s.
Figure 10. PCR amplification of the cDNA continues through 40 cycles.
When PCR begins, the cDNA templates as well as the amount of dsDNA are at
low concentrations and the reagents are in excess. This prompts the amplification
procedure to take place as primer binding does not have to compete with product
renaturation. The amplification is only linear in this constant exponential stage. The rate
decreases as reagents get used up and ceases to be linear once the product renaturation
starts to compete with the primer binding. At some later cycle the amplification rate
plateaus, and little more product is made. It is during the exponential stage of
amplification that level of expression can be compared across samples at a given cycle
number to generate accurate starting copy numbers.
As explained in Section 2.2.1 above, AR expression should be present throughout
the tissue section. However, q rt-PCR allows us to quantify the level of expression by
evaluating the starting copy number for each of the sections individually at the same
number of cycles during the PCR process. Figure 11 shows a schematic of a tumor
boundary identified by analysis of each of the sampled sections within the grid. The
yellow region indicates high levels of AR expression.
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Figure 11. Analysis of tissue sample to identify regions showing expression of the AR tumor marker.
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Chapter 3 The Tissue Sampling Process
3.1 The Anatomy of the Device
Figure 12 shows a schematic of the device with a tissue specimen in place before
cutting. The major instrument components are labeled.
Voice Coil Actuator
Agitating prongs
~1~TBladeura
Cooling Tray
- - --- --- 
Weil lte
4 Z axis stage
Figure 12. Schematic of the main elements of the tissue sampling device.
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3.2 Three Step Process
The instrument has three well defined functions. The first of these is to cut the
tissue specimen into the grid sections. In Figure 13 below, the first panel shows the
device in its initial position with the sample on the cutting surface. In panel two, the
cutting surface is advanced towards the blades until the specimen is sectioned. The last
panel shows that after the cutting surface is removed, the tissue specimen is held between
the blades in the array directly above the well plate.
Figure 13. Schematic of the device cutting a sample.
The second function is to efficiently transfer the separated sections into the well
plate beneath. The first panel of Figure 14 below shows that the well plate is advanced
towards the blade array and is pre-aligned to match the grid of blades. The second panel
shows the movement of the agitating platform as it is lowered towards the tissue to push
the sections out of the blades and into the well plate. In the last panel the tips of the
prongs are immersed in the mixture of tissue and extraction buffer in the well plate.
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Figure 14. Schematic of the transfer of the tissue sections from the blade array to the well plate
containing buffer.
The final function of the instrument is to homogenize the tissue in each individual
well. This is performed by actuating the voice coil that is attached to the agitation
platform. The resulting sinusoidal movement of the prongs in the mixture thoroughly
mixes it, decimating the tissue as shown in panel one of Figure 15. Lastly, the well plate
containing the homogenized mixture is lowered away from the prongs and the isolation
process is continued using the Qiagen DNeasy protocol.
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Figure 15. Schematic of the homogenization action of the instrument.
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3.3 DNA/mRNA isolation
Tissue swuplos
Lys7
- - -
Wash
EOut#
Ready4o-us DA
Figure 16. DNA/mRNA purification procedure
(copied from the Qiagen D'Neasy handbook).
The next step in the sampling process is the
isolation or purification of the genomic
DNA or mRNA from the rest of the tissue
fragments. At this point, this is
accomplished using the protocol and
purification kit developed by Qiagen. Figure
16 at left, shows a schematic of the
purification process. In the first step, tissues
are lysed as outlined in the previous section.
After lysis, the DNA or mRNA selectively
binds to the silica-gel membrane in the well
plate and contaminants are either vacuum
suctioned (using the Qiagen vacuum pump)
or spun (using a 96 well plate centrifugation
system) into the collector plate below.
Remaining contaminants and enzyme
inhibitors are removed in two wash steps.
Pure DNA or mRNA is then eluted in water
or a low-salt buffer and is ready for
amplification (see Appendix ## for protocol
details).
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3.3 Amplification of the AR
The Roche Lightcycler 2.0, pictured in Figure 17 below, is used to perform rt-
PCR or q rt-PCR on the DNA or mRNA isolated from the tissue sections respectively. In
the experiments to be presented, primers specific for the amplification of a 154bp AR
fragment were used in the PCR. Primers yielding a 110bp -Globin fragment provided a
positive control for the reaction while PCR grade H20 was used as a negative control.
Figure 17. The Roche Lightcycler 2.0 (copied from Roche-Diagnostics).
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Chapter 4 Device Requirements
4.1 High Throughput geometrical specifications
The overarching goal of this instrument was to be able to detect tumor boundaries
in a frozen tissue sample. As discussed in Section 2.3.2 above, systems that have been
developed, take sample cores at distinct points along the tissue. However, unlike other
TMAs, the instrument continues to use the entire square area that is sectioned instead of
using only small circular sections. The effect is that there is no chance that markers will
be missed by analyzing only a portion of the section ensuring that very little or no
information is lost.
The tissue sampling device was designed, not only to take as many samples as
possible, but to interface with, and therefore complement the geometry of the 384 well
plate, pictured in Figure 18, into which the tissue samples are transferred. The use of the
384 well plate as a depository also helps to facilitate the total separation of the samples
from each other after they are cut to avoid cross talk among chambers.
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Figure 18. The 384 well plate where DNA/mRNA/protein isolation begins.
The well plate, as it is already clearly labeled, makes spatial-molecular
relationship of the samples effortless to track.
4.2 Specimen Preparation and Temperature Regulation
The single drawback of using the 384 well plate is that it constrains the size or
volume of the tissue sample that can be taken. Each well can hold a maximum of 35 pl.
With the delicate balance needed between the tissue sample and the extraction buffer
volume, the tissue volume is restricted to approximately 3.8 pl. With the 4.5 mm by 4.5
mm surface area, the maximum thickness of the sample that can be analyzed using this
device is 150 gm. This maximum thickness was used in estimating the amount of DNA
or RNA that could be found in the sample. The first key assumption was that there was
0.2 to 1.2 pg of DNA per milligram of tissue' 4. This is used to estimate the maximum
final yield from the isolation process. For lung and liver tissue, an average of 0.7 pg per
milligram of tissue before isolation was used. In the case of pancreatic tissue however,
more RNA is expected, so the estimate used was higher than 0.7 Ag per milligram of
14 Qiagen DNeasy Tissue Handbook March 2004
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tissue. Another key assumption was that a 2 mm cubed block of tissue has a mass of
approximately 10 mg.
Table 1. DNA yield calculated based on specimen thickness
section volume
(M 3 . 10-9)
Section mass
(mg)
microgram of
DNA/ mg of tissue amt of DNA (pg)
1.00 20.25 25.31 0.7 17.72
0.80 16.20 20.25 0.7 14.18
0.66 13.37 16.71 0.7 11.69
0.50 10.13 12.66 0.7 8.86
0.30 6.08 7.59 0.7 5.32
3.04 3.80 0.7 2.66
All sectioning and cutting required that the tissue samples be kept frozen. For the
testing and characterization of the instrument, fresh tissue was harvested from a guinea
pig. The pancreatic gland, the lung and the liver were removed and immediately frozen in
liquid nitrogen to reduce degradation of the DNA and RNA. These organs were then set
in 20 mm sided cube blocks of optimal cutting temperature (OCT) compound that
preserved the shape and temperature. Sections of 150 stm or less were obtained using the
Vibratome UltraPro 5000 cryostat shown in Figure 19.
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0.15
Figure 19. Cryostat used to cut 30 Am sections of tissue set in OCT.
The cryostat regulates the temperature of the interior chamber where the blade
and the OCT sample are clamped. The cryostat can yield sections of 4 to 30 itm.
After the sample is cut, it is removed from the metal plate and transferred to a plastic
coverslip. A small coating of glycerol is used to help the dry OCT embedded tissue to
adhere to the plastic coverslip. A successful transfer is shown in the panels below in
Figure 20.
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Figure 20. Section transferred to plastic cover slip.
The pancreas, lung and liver from the guinea pig were the glands and organs
chosen for testing as they were the best available to emulate the consistency, texture and
weight of human glandular tissue. These types of glandular tissue, breast tissue in
particular, are prone to fracturing during frozen sectioning. They are also softer than
muscular tissue.
4.3 Cutting Requirements of the Tissue Sampling Device
During initial tests, it was found that very high (greater than 50 N) forces were
needed to cut samples that were approximately 1 mm thick. The maximum thickness of
archived samples is usually less than 1 mm.
In order to prevent cracking of tissue ensuing from such forces several different
methods of cutting were tested. The first method used a blade array, much like the final
design, that was ultrasonically vibrated in order to microscopically melt and therefore cut
the tissue in the path of the blade. An ultrasonic welder from Stapla Ultrasonics
Corporation was used to test this method. The vibration reduced the force necessary for
cutting to near zero. However, sample loss, particularly degradation of RNA, along the
edges of each section was anticipated as a result of the heat generated by friction. While
this method showed potential, accurate temperature sensing could not be achieved within
each section of tissue.
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Another innovation was to use a laser cutter to cut 1 mm by 1 mm sections, the major
issue being to keep the tissue sample frozen throughout the process. While this appeared
to work initially if the tissue was placed in a liquid nitrogen bath, it became apparent that
the local temperature could not be monitored during cutting.
While looking for alternatives to the use of brute force to cut sections, transfer to
individual wells of a 384 well plate was integrated into the process. This reduced the
thickness of the tissue significantly resulting in forces of less than 10 N being required to
cut the tissue sections. This added much needed flexibility when selecting cutting options
and eliminated the need for real time in process temperature sensing as very little heat is
put into the system when smaller forces were required. Force for tissue sectioning is
provided by a stepper motor driven z-axis stage that advances the tissue towards the
blades until the blades contact the cutting block surface. This method required that the
tower be clamped to the optical table in order to exert forces on tissue.
4.4 Tissue Transfer and Tissue Buffer Mixture Containment
There are several challenges inherent in the transfer of the tissue from the blade
array where it is held by friction to the well plate beneath. The first challenge is that the
tissue must remain frozen for some time after cutting so that cutting block can be lowered
and removed. In addition, the plastic cover slip also needs to be removed without
dislodging the tissue from its position in the blade array. The next complication involves
the stiffness of the tissue and its resistance to being pushed into the well plates by the
agitating platform prongs. Ideally, the tissue needs be warmed up to room temperature
before entering the buffer solution in the well plates. However, if the tissue warms too
quickly, transfer will be ineffective as the prongs will not be able to push the melting
microblocks of tissue into the wells.
Installing a motorized z-axis stage to move the well plate made the transfer of the
blade array from above the cutting block to the top of the well plate quick, keeping the
tissue frozen throughout the move.
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Qiagen will soon market a vacuum 384 well plate making transfer from the wells
to individual spin columns unnecessary. This vacuum well plate circumvents the need to
centrifuge well plates, instead it uses similar spin column technology to bind nucleic acid
and vacuum suctions the suspension through to a similar plate beneath under appropriate
buffer conditions.
4.5 Mechanical cell lysis
Careful examination of some of the existing options for reagent-less mechanical
lysis ruled out total mechanical tissue lysis by the device. For instance nanoscaled barbs
in microchannels present by Di Carlo et al15 or the use of metal beads on a disk spun
forward and backwards at high accelerations documented by Kim et al1 6need to occur on
a scale orders of magnitude smaller to achieve entirely mechanical lysis. Some of the
basic requirements for an actuator for microscaled mechanical lysis were a fairly low
frequency of 50 to 100 Hz and a displacement of approximately 1 mm with 100 Am
precision. One actuator that was considered was the Inchworm Adantage 17. This
instrument quickly helped to redefine device requirements as its precision was so nice
that a step size of 0.5 Am with a piezoelectric range frequency (maximum 1000 Hz)
would cleanly penetrate cell membranes, avoid dimpling and leave the cell intact. Since
this is not the goal of mechanical cell lysis, this precision instrument was passed over for
cruder, more destructive options.
15 Di Carlo D., Jeong K. and Lee L. Reagentless mechanical cell lysis by nanoscale barbs in microchannels
for sample preparation. Lab Chip 3:287-291, 2003.
16 Kim J., Hee Jang S., Jia G., Zoval j., Da Silva N. and Madou M. Cell Lysis on a microfluidic Compact
Disk. Lab Chip 4: 516-522, 2004.
17 http ://www.exfo-lifesciences.com/products/LSS-8000/specs.pdf
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Chapter 5 Design and Fabrication
5.1 The Device
~vb ~
Figure 21. Tissue Sampling Instrument.
The entire device stands approximately 0.3 m tall with the major components
labeled in Figure 21. Although not clearly seen above, the heart of the device is the
platform that cuts and then facilitates the transfer and homogenization of the tissue. These
components, the blade array and the agitation platform are individually less than 25 mm
in height and stack together neatly to reduce the total translational motion of the tissue.
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Likewise the tower was built to minimize movement of components with the cutting and
cooling platform stacked above the well plate. In the following sections, component
design will be detailed.
5.1.1 The Cooling Tray
The cooling tray shown in Figure 22 below actually serves a dual purpose.
Fabricated on the Haas VF-OE Milling Machine, a 3/5 axis machining center, its center
post provides a non compliant, heat conductor for the tissue to rest on as it is being cut.
The moat like well around this post holds the dry ice that is required to keep the
temperature of the sample sub zero prior to and during cutting.
Another significant feature of this component is that it is elevated on delrin shanks to
accommodate the well plate beneath it. The delrin also serves as an excellent thermal
insulator of the aluminium from the rest of the device, allowing the store to last longer as
well as protecting the well plate contents below from freezing. This cutting tray is
removed from the tower as soon as the tissue has been cut and held in the grid of blades.
Delrin allows the entire tray to slide out from the tower readily and to be replaced with
ease.
42
Figure 22. Dry ice tray and tissue cutting block.
5.1.2 The Cutting Tool
The tool designed to cut the tissue specimen, shown in Figure 23 is made up of
carbide steel razor blades held together by a base of cured plastic resin. Its overall
dimensions are 22 mm square with a total height of 8 mm. Each blade is approximately
230 ym in thickness and protrudes out of the resin 3 mm. They are structurally aligned by
cutting 3 mm slots at 4.5 mm spacing along the length of the blade so that blades can
interlock. This is accomplished by cutting into the cutting edge of the bottom row of
blades and the blunt edge of the top row. The bottom row, with slots in the cutting edge,
is set into the resin first. The 250 Am slots were cut into the steel blades on the Wire
Electric Discharge Machine (EDM), which uses a high voltage pulse to melt and vaporize
the material in the path of the wire through the dielectric fluid in which is it immersed.
This process exerts no force on the work piece being machined with accuracy on the
order of 10 Am. Ultra Violet Loctite Glue was used to secure the blades into the resin
base.
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Figure 23. Blade array for cutting tissue into sections.
The base for the blade array was fabricated in the Viper SLA system which
allowed for 100 /Am resolution. The slots for the blades were spaced 4.5 mm apart with
3.75 mm sided square holes between them to allow access to the tissue from the back of
the array.
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Figure 24. Top view of the Unigraphics solid model of the blade array base showing through-holes.
The base, shown in 3D below in Figure 25 is only 5 mm thick so that it can be
mounted into the macrobench fixture in the device tower (Figure 21) with the blades
protruding down towards the cutting block. This resin, Accura SI 40, has high
temperature resistance and is durable after curing with low linear and differential
shrinkage18 producing excellent resolution, however it has proven toxic when in contact
with biological materials and therefore could not be used in direct contact with the tissue
sample at any point in time.
18http://www.3dsystems.com/products/datafiles/accura/datasheets/Accura_SI_40_Ar_Hc-SEngl_0204.pdf
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Figure 25. Isometric view of blade array base.
5.1.3 Translation and Alignment Considerations
The array built for this prototype contained 16 wells. In order to transfer tissue to
the well plate successfully, the device was adapted to allow horizontal x and y axis
movement from which all three hundred and eighty four wells could be accessed. The
well plate and cutting tray above it were mounted on top of a pair of manual single axis
stages. The stages provided translation along perpendicular wells of the plate. It also
allowed for fine adjustments to the initial position of the wells beneath the blade array to
ensure that the blades seat well onto the top of the plate eliminating the possibility of
cross talk among tissue sections and well contents during homogenization.
The choice of blade thickness and well containment were ideal for the snug fit of
the blade cutting edge into the grooves between wells in the plate. When the array is
seated, as shown in Figure 26 below, it becomes difficult for horizontal disturbances to
dislodge the array from the plate.
46
Figure 26. The blade array in position above wells of the plate. [Insert: close up of blade seating]
Another key component in translation is the motorized z axis stage for vertical
movement of the entire lower carriage towards the stationary blade array platform. This
stage is crucial in the quick tissue transfer as it is programmed to run through a series of 5
steps for the sampling process (see Appendix A)
The Parker Positioning Systems one axis stage was driven using a stepper motor
with a resolution of 5000 steps per mm. Used in conjunction with a Parker 6104 Zeta
Compumotor indexer drive, commands for translation could be programmed in Visual
Basic and sent directly to the motor, commands could also be sent using the command
prompt or using the hyper terminal communications port.
5.1.4 Tissue Transfer and Homogenization
When the tissue is cut, it is imperative that it be transferred to the well plate
containing the lysis buffer quickly. The process has two steps. The first step entails the z
axis translation stage moving up to interlock with the blade array as described in the
preceding section. The second is the actuation of the agitation platform. It is lowered
through the blade array, contacts the tissue sections and pushes the sections through to
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the wells directly below. Although this action is intended to be solenoid actuated, in this
prototype, the action is manual and must be done quickly, but carefully since softer tissue
may be penetrated instead of transferred as it warms up. The stainless steel prongs in their
housing can be seen in Figure 27.
Figure 27. Sixteen prong platform attached to the voice coil actuator.
Each row of prongs was cut from 250 pm thick steel shim stock using the Wire
EDM. The T shape at the head of the prong was chosen to increase contact area with the
tissue during transfer but more so to increase the efficiency of homogenization. The
sharper square edges are likely to aid in the mechanical breakdown of the tissue. Figure
28 shows a scaled drawing of a single row of prongs used in the computer aided
machining of the part. The wider end of the prong array fits snugly into an acrylic holder
housed in a resin chamber made in the Viper SLA.
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Figure 28. Outline of prong array cut from steel shim stock.
After successfully transferring the tissue to the well plate, the homogenization
process begins. A Brnel and Kjor Type 4810 voice coil actuator is used to provide the
disturbance necessary for homogenization of the tissue. This voice coil has a 6 mm
maximum displacement, but satisfies the device requirements as the displacement can be
controlled by the changing input voltage to the system. Agitation was optimized at a 3
volt peak to peak 70 Hz frequency square waveform. The signal is generated by an
Agilent 33120A frequency generator and amplified using a Techron Power Amplifier.
The calibration of the actuator with the agitation device attached can be found in the next
section.
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Figure 29. Before and after the prong platform is actuated to transfer the tissue sections.
As mentioned previously, this device is expected to be used in conjunction with of
the emerging vacuum technology for the 384 well plate format. When designing the
prototype, it was necessary to make some assumptions about a product which is not yet
on the market. The main assumption made with respect to the vacuum technology was
that the 384 well plate would retain the same depth dimensions of the currently existing
96 well plate used with the vacuum suctioning. The height from the top of the 96 well
plate to the membrane is currently 29 mm. The prongs in this prototype were restricted to
a displacement of only 8mm so that there would be no possibility of puncturing the
delicate membrane during homogenization. Figure 29 above shows the blade array with
the agitation array stacked above it. In the second frame, the platform is lowered and the
prongs protrude into area that contains tissue and lysis buffer inside the wells.
For the purposes of proof of concept and biological data collection, after
homogenization, the mixture is transferred to regular microcentrifuge tubes for isolation
of nucleic acid. A 154 or 152 bp fragment of the AR is then amplified using the rt-PCR..
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5.2 Device Characterization
5.2.1 Instrumentation
Several supplementary Briel & Kjor instruments were necessary when using the
Type 4810 voice coil actuator to drive the homogenization process. These included an
impedence head for generating the force and acceleration signals, two amplifiers, one for
each signal as well as a Calibration Exciter with which to calibrate the impedence head.
The voice coil specifications for 65 Hz to 4 kHz are detailed in Table 2. In this range, the
actuator reaches a maximum force depending on its effective mass and the acceleration to
which it is driven.
Table 2. Bruel and Kjar Type 4810 Voice Coil Actuator Specifications
Force Rating 1ON
Max Displacement 6 mm
Dynamic Stiffness 2 kN/m
Dynamic Weight of the Moving System 0.18 N
Max Input Current 1.8 A RMS
Peak Acceleration for Bare Table 550 ms2
Nominal Impedance 3.5 Q at 500 Hz
With a load of 0.075 kg, comprising the total mass of the moving element of the
voice coil with effective mass, me = 0.018 kg, the Brael & Kjor Type 8001 impedance
head, mi, at 0.031 kg and the mass of the agitator, ma = 0.026 kg, the force that the table
can exert is governed by Equation 1;
F = mta, (1)
where mt= me+ mi+ ma. (2)
The Briel & Kjer impedance head is mounted directly to the table of the voice
coil, with the agitator mounted at the other end. It measures both acceleration of the
system and the force exerted by it. Two Brilel & Kjor Charge Amplifiers (Type 2635) are
used to convert the output signals from the impedance head to voltage measurements.
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The charge sensitivity settings used and the previous voltage sensitivity calibration are
shown in Table 3 below.
Table 3. Calibration Chart for Type 8001 Impedance Head.
Accelerometer Force Sensor
Charge Sensitivity 0.382 pC/ms2 3.53 pC/N
Voltage Sensitivity 0.336 mV/ms2 3.61 mV/N
5.2.2 Data Acquisition
Data from the amplifiers was acquired using a National Instruments Data
Acquisition Card (NIDAQ) and BNC - 2110 connector block. The shielded connector
block with signal labeled BNC connectors allowed easy connections from analog devices
and the data was captured using LabView software. The block diagram of the Lab View
program is shown in Figure 30. This program was intended to collect data during the
recalibration of the impedance head and during the tissue sampling process to determine
the displacement of the agitating prongs as well as the force exerted during the
homogenization process.
nesm"e
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Figure 30. LabView Block Diagram for Data Acquisition.
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Figure 31, the user interface for the LabView program used in these experiments,
shows a snapshot when the voltage input is off. The three signals displayed, voltage in,
force voltage signal, and the acceleration voltage signal are all recorded at a preset
sampling rate and for limited voltage ranges. Data can be written to files for analysis and
the sampling rate can easily be adjusted from test to test.
Figure 31. Front Panel GUI of LabView program.
5.2.3 Sensor Calibration
A short test was run to recalibrate the sensor for the system. Using a BrUel &
Kjor Calibration Exciter Type 4294 as a vibration reference source, the output of the
impedance head could be calibrated for acceleration and force. The sensor was attached
directly to the calibrator table, using a 10-32 UNF steel stud, a standard connection for
most impedance heads and accelerometers. It is then driven by the calibrator which
contains a crystal oscillator at a frequency of 159.15 Hz. This oscillator drives the
electromagnetic exciter which is monitored by a small internal accelerometer on the
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underside of the vibration table. This provides feedback to maintain an accurate vibration
independent of the mass of the sensor.
the
the
The data collected from the test was then curve fitted for the known frequency of
calibrator to obtain a relationship between the voltage output from the amplifier and
acceleration of the sensor. The exciter standard acceleration level was 10 ms-2 RMS.
x 10~
0 0.002 0.004 0.006 0.008 0.01
Time (s)
0.012 0.014 0.016 0.018 0.02
Figure 32. Curve fit for acceleration-voltage calibration.
The RMS of the sine function obtained, Equation 3,
V = -0.0019 + 0.00434 - sin(1000t - 0.6) (3)
is found to be approximately 3.452 - 10-3 V. Similarly, curve fit for the Force calibration,
shown in Figure 33, results in Equation 4,
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V = 1.381 -sin (1000t+39.87),
with an RMS of 0.976 V. These are summarized as voltage sensitivities in Table 4.
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Figure 33. Curve fit for force-voltage calibration.
Table 4. Recalibration of sensor compared to standard calibration.
Accelerometer Force Gauge
Voltage Sensitivity 0.336 mV/ms-2 3.61 V/N
Sensitivity Recalibrated 0.345 mV/ms-2
The maximum voltage peak to peak that the voice coil was driven at was
approximately 3.0 V. In Figure 34 below, the series of graphs show that this voltage
produced an average displacement of 2 mm. The arbitrary peaks on the force versus time
graph indicate that there is some external disturbance on the system. This is most likely
due to interaction with tissue in the well plate to produce the larger forces of
approximately 2.5 N that are detected.
55
0
I I I I I I --
3.14 V/N
(4)
-
.
-- A A A A -- A 
/ \ 02 \ 0/ 1 0.08 .1 .12 0. 0 1 \0.18 j
vI \IVV\J
0 110.04V 6 0.08 0. .12 0.14 . 6 0.18 C
Time (s)
Id
2
,2
Figure 34. Graphs showing Force, Acceleration and Displacements during homogenization.
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Chapter 6 Results
6.1 Effectiveness of Transfer Process
Initially, the best method of determining how well the transfer process worked
was to observe the contents of the well immediately after the transfer was complete
without continuing to the homogenization process. Nine separate observations were
performed over the period of a month. After each iteration, the design was reworked to
improve transfer. For instance during the first observation, tissue could only be found in
one of the 16 wells. This was due to misalignment of the agitator array. The housing for
the array was consequently rebuilt with tighter tolerances and was no longer a hindrance
in further trials and transfer improved to four of 16 wells. Other improvements of the
design included changing the width of the agitator prongs, as well as coating the blades in
glycerol, a protein friendly medium, to reduce the static friction. It was found that on
average nine of the 16 wells had tissue by the end of the optimization process. The wells
shown in Figure 35 were almost always observed to contain homogenized tissue.
However no correlation among these wells, the prongs, or their position with respect to
the tissue was could be ascertained.
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Figure 35. Schematic of wells with high probability of containing tissue.
Following transfer and homogenization, the homogenate from each well was
transferred to individual Qiagen columns for isolation of nucleic acid, more specifically
genomic DNA as discussed in Section 3.3.
The relative amount of genomic DNA recovered from each section of the grid
following Qiagen extraction was determined using the PicoGreen@ dsDNA
Quantification Kit from Molecular Probes. The PicoGreen@ reagent was selected for its
sensitivity and for its large range. Sensitivity was essential as it was used to determine
whether the un-amplified samples contained dsDNA and, if so, at what concentration.
PicoGreen also maintains a linear detection range even in the presence of salts, ethanol,
detergents, proteins and agarose; common compounds that contaminate nucleic acid
preparations.
PicoGreen along with other fluorescence dyes binds nucleic acids during
incubation. When excited by the spectrofluorometer at 480 nm, the sample fluoresces and
emits at 520 nm. This is detected by the spectrofluorometer, which generates a
fluorescence value for each sample. The value for the reagent blank is then subtracted
from that of each sample. To evaluate the concentration of nucleic acids in the unknown
samples, serial dilutions of a known concentration of human genomic DNA were used to
generate a standard curve as shown in Figure 36. A log-linear curve fit was applied to the
data.
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Standard Curve for PicoGreen dsDNA sensitivity
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Figure 36. Standard Curve for PicoGreen.
For the set of unknown samples shown in Figure 37, a low range curve was first
calculated, but the fluorescence observed in the unknown samples exceeded the
maximum standard curve value. A high range curve was then run against the samples and
although similar problems arose, a two fold dilution of the unknowns was sufficient to
allow interpolation of concentrations for the unknowns from the standard curve
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Figure 37. Fluorescence values from a tissue sample.
Although the PicoGreen cannot help to distinguish between dsDNA, single
stranded DNA (ssDNA) and RNA, Quant-iTTM boasts that excitation at 480 nm produces
a much larger response from dsDNA than either ssDNA or RNA and that ssDNA and
RNA increase signal intensity by no more than 10%. One can safely assume then, that the
samples numbered two, three and four above do contain double stranded DNA arguing
that the tissue sampling device can be used for the isolation of nucleic acid.
6.2 Product Quantification using Real Time PCR
6.2.1 Preliminary Trials
Although the PicoGreen fluorescence gave an approximate quantification of the
nucleic acid present in the sample shortly after isolation, more accurate quantification can
be obtained using real time PCR (rtPCR). Using specific primers, a segment of interest
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can be amplified in the LightCycler in the presence of a fluorescent intercalating dye and
the fluorescence documented using the LightCycler 2.0 software. The starting
concentration of that segment can be back calculated. In order to verify that only this
segment is amplified, after PCR, a polyacrylamide gel can be run to examine the length
of the segments amplified. These two pieces of information verify that the device is
performing the delicate task of extracting DNA worthy of use in profiling cancerous
tumors.
Two specific primer sets were identified for use during experimentation. The 3-
Globin primer set amplifies a 110 bp segment and was chosen as an easy to use positive
control for comparison with the more finicky androgen receptor (AR) primers. Among
the range of AR primers used, the first to be tested was an intron 7 based forward primer
for the AR (modhAR Fl) in combination with an exon 8 based reverse primer (modhAR
Ri), designed to amplify a 154bp fragment of the human AR. Using an intron based
primer ensured that only genomic DNA would be amplified as introns would be missing
from spliced RNA. The modhAR Fl/R1 primers, whose sequence is detailed in Appendix
C, were used to generated most of the preliminary data in this document. Another primer
set used during testing amplified a much larger segment, approximately 646 bp.
Unfortunately, this large segment proved more difficult to amplify, because amplification
involved replicating from through the entire intron 7, this involved the matching of
approximately 1000 nucleotides. Finally, the primer set that was eventually used to
generate the final standard curves and to analyze the unknown samples was the modhAR
F2/R1 set which amplified a 152 bp segment in the same region as the modhAR Fl/Ri
primers.
To simplify this process, two Roche Applied Science PCR kits were purchased; the
first contained the f-Globin primer mix. The second kit, LightCycler@ FastStart DNA
MasterLus SYBR Green1, contained the master mix composed of dNTPs, polymerase,
and SYBR Green, a fluorescent dye that intercalates into dsDNA. As PCR progresses,
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dsDNA is synthesized and fluorescence increases' . This kit was designed for more
robust PCR to avoid time consuming optimization steps reducing set up time.
Serial dilutons of the human genomic DNA were used in combination with the a-
globin primer set to generate a standard curve; the amplification curves are shown in
Figure 38. Obtaining a good standard curve for the dilution series is the key to
quantifying the starting concentration from unknown samples by interpolation.
ModhAR Fl/Rl primers were used to amplify both serial dilutions of the Roche
supplied human genomic DNA (a positive control for primers) and unknown
concentrations of the 16 guinea pig samples. PCR grade H20 was used as a negative
control in these experiments.
The rt-PCR was cycled 45 times. A detailed description of the PCR protocol can
be found in the Appendix C. Figure 38 reveals that the 30 pg and 3pg dilutions crossed
threshold within one cycle of the water blank instead of 3 to 4 cycles before. The more
concentrated dilutions however, behaved as expected. Similar results were observed in
Figure 39 below for the modhAR FI/R1 dilutions.
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Figure 39. modhARF1/R1 primer amplification of stock DNA.
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Figure 38. fl-globin primer amplification of stock DNA.
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The PCR products generated above were further analyzed by polyacrylamide gel
electrophoresis (PAGE) with the intention of identifying sources of error that contribute
to the unusual amplification profiles. PAGE is a commonly used method for separating
nucleic acids and proteins based on two principles, the macromolecule charge and the
mass or length of the segment20 . An electric field is applied across the gel with the
positive terminal at the opposite end from the wells where the samples are deposited. The
negatively charged nucleic acids are attracted to this terminal and attempt to migrate
across the gel. The gel composition however inhibits progress based on the segment size.
A 5% polyacrylamide gel was used to separate the PCR products. PCR product from both
the 0--globin and the modhAR primer sets (a positive and negative control of each)
together with PCR products generated using the modhAR primer set and guinea pig
genomic DNA (unknowns) were each loaded into individual wells on the gel. A 100 bp
ladder was loaded to provide a set of known fragment sizes. The gel was electrophoresed
at 1 OOV until the bromophenol marker dye in the sample loading buffer had migrated
three quarters of the way down the gel. The gel was then removed, stained with 0.5
pg/mL ethidium bromide and photographed using the Canon 1DS. Using an image
processing matlab program (see Appendix E), the gel bands were intensified in order to
aid assessment of the relative concentration of expected products. The augmented image
is shown in Figure 40.
20 http://www.bergen.org/AAST/Projects/Gel/
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Figure 40. Image of gel after Matlab image processing.
The first two lanes running from left to right contain the PCR products generated
using the -Globin primer with the positive control in lane 1 and its negative control in
lane 2. A major band of 110 bp is observed in the positive control as expected. A band of
comparable size in the negative control suggests some sample contamination. Lanes 3
and 4 contain the PCR products generated using the modhAR primer set and human
genomic DNA. A band of 154 bp is observed in the positive control consistent with
amplification of the expected AR fragment while no bands are observed in the negative
control as expected.
Multiple bands of varying intensity are observed in the PCR products generated
using the modhAR primers and guinea pig genomic DNA. Bands of approximately 154
bp and 200 bp are observed in combination or alone in all unknowns. An additional band
of approximately 430 bp is observed in almost all unknowns. The 200 bp fragment is the
major PCR product observed in lanes 9, 10, 13 tol5, and 17 to 20. These lanes
correspond to five out of the eight wells with a high probability of transfer from tissue.
Although these results indicate that the target sequence was not the major product
amplified, there are many factors that may have affected the amplification. One distinct
possibility is the non specific amplification of a 204 bp fragment whose primers (see
Appendix C for exact sequences) are similar to those for the modhAR primer set used.
The forward intron 7 primer is identical to the modhAR Fl and the reverse primer
although dissimilar, if there is some heterogeneity in the length of the guinea pig genomic
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DNA encompassed by these primers, then, it would be possible for the 204 bp fragment
to be amplified lengthening the expected sequence.
Non-specific amplification products can also have been generated because of a
lack of optimization of the annealing temperature of the primers in these reactions. This
tends to occur when the annealing temperature set for the amplification cycle is too low
and primers settle on the wrong sequence of nucleotides. In addition, non specific
amplification can occur if either the genomic DNA or the primers used are degraded. It is
unlikely that the DNA was degraded as the major product is actually larger than the target
sequence indicating longer intact strands than chopped up DNA. Primer degradation is
also unlikely as these primers amplified the genomic DNA, verified by the 154 bp band
on the positive control in lane 4. Optimization of the process would answer many of these
questions.
6.2.2 Optimization
Optimization of the PCR process began with an examination of sources of
contamination. The PCR grade water supplied in the Roche kit and used in all
experiments until this point was tested along with the PCR grade water purchased from
an independent company, Ambion. This verified suspicions that the Roche water had
been contaminated as the Ambion water (negative control) repeatedly amplified 2-3
cycles after the Roche water.
Another optimization step that was included was the regulation of MgCl 2
concentration in the PCR master mix. A new Roche kit was bought that allowed the user
to add a specific MgCl 2 concentration. Previous SYBR kits used contained a Masteros
PCR mix that did not indicate the concentration included, nor did it allow for varying the
concentration for optimization of the amplification.
Also, to ensure that the primers being used were still in working order, a non
quantitative amplification was done. This PCR was set up using the base components of
the master mix such as dNTPs. PAGE was once again used to analyze the product from
this PCR procedure and demonstrated that the modhAR primers were amplified as
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expected with no contamination occurring in the negative control. Although these
primers appeared to be uncontaminated, the lagging amplification of the less concentrated
dilutions prompted the purchase of a new primer set.
The new primer set, modhAR F2 and R2 targets the same region as the previous
combination. Unfortunately, since the AR region is difficult to prime due to an
abundance of secondary structure, not only did the R2 primer fail several times in
preparation, but this resulted in the use of the F2 primer with R1 until the completion of
testing of the device. The pairing of these primers produced similar amplification
profiles to the modhAR Fl and Ri, amplifying a 152 bp segment instead of 154 bps.
6.2.3 The Crossing Point and Standard Curves
The objective of using quantitative PCR to determine the effectiveness of the
sampling device is its ability to estimate the initial concentration of DNA present.
Quantification requires that during PCR amplification of a segment, the sample
fluorescence signal rises to some arbitrary level above the background. At this arbitrary
level, the crossing point (CP) for the sample can be identified and used to estimate the
initial concentration of DNA in the sample. Since the crossing point is dependant on the
initial DNA concentration, when a sample has a higher concentration its crossing point
will occur at a lower cycle number.
The arbitrary level at which the crossing point occurs depends on the type of
analysis used. Using the LightCycler 2.0 Instrument software, there are two methods of
analysis provided, the first method, chosen for the analysis of all the samples during
experimentation is the Automated Method. This method identifies the crossing point of
the sample as the point where the sample's fluorescence curve turns sharply upward. This
turning point corresponds to the first maximum of the second derivative of the curve.
The second method, the Fit Points Method, converts a sample's exponential curve
to a straight line. The line is then extended downward until it intersects a horizontal line,
the crossing line; this intersection is the crossing point. This method requires the user to
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perform most of the analysis manually by adjusting the sample curves to start at the same
baseline, as well as eliminating any background fluorescence that is present in the data.
The CP identification is the basis for generating standard curves which are used to
estimate the initial concentration of unknown samples when using the same primers. The
CP data for a dilution series of human genomic DNA using both sets of primers, the 1-
globin as well as the modhAR F2 and Ri, were obtained. These trials were repeated at
least 5 times each. The average CP was calculated for each dilution and plotted on a log-
linear plot versus the concentration of the human genomic DNA. Figure 41 shows the
log-linear curve fit to the data to generate the standard curve equations.
Standard Curves
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Figure 41. Standard curves generated for Beta-globin and modhAR primers.
The 0-globin primer set responded well to the optimization techniques producing
a good standard curve across the dilution series of the human genomic DNA.
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Unfortunately, the modhAR F2 and R1 primer set did not produce a similar profile. For
the lower initial concentrations amplified in the 0 to 30 pg/gIl range, the CPs were
consistently lower than expected. A log-linear fit could not be obtained for the entire data
range; however, for the range in which the unknown samples have been estimated to fall,
300 to 30000 pg/pl, the data collected was a good log-linear fit. Equation 5 below is the
standard curve used to calculate the initial concentration of the unknown samples.
CP = -0.785 - logio(N) + 37.18, (5)
where N is the initial concentration.
The slope of the standard curve or the "efficiency" of the curve is expected to be 2, the
product of a perfect amplification reaction. In reality however, reactions often have a
lower efficiency. Interestingly, the slope of the standard curve generated is 0.785 for the
modhAR and 1.115 for the -globin attesting once again to the difficulty of coaxing even
more than 50% efficiency from the modhAR primers.
To account for this, one can extrapolate the data by introducing a probability of
amplification variable2, p, into the amplification equation,
Nc = No (1+ p)C, (6)
where C is the cycle at which Nc is the concentration and No is the initial concentration.
This leads to a standard curve equation when C = CP, then Nc = Ncp
CP = logiO T) - log, oNo). (7)
logio(l+ p)
Along with the variation of amplification efficiency, each experiment was subject to
pipetting process errors that varied widely depending on the skill of the operator. These
errors combined to produce the occasional outlier observed in the data and a more the
consistent random error in all the data contributing to large variances (see Appendix F).
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6.2.4 Instrument Sampling Performance
Based on the PicoGreen tests in Section 6.1, the instrument appears capable of
transferring large amounts of nucleic acid. In this section a quantification of the actual
target sequence that was transferred will be presented.
Amplification of the putative guinea pig genomic DNA extracted from tissue
sections is shown in Figure 42. These 16 unknown samples cross threshold at a point
intermediate between the negative and positive controls. The variation in CP between the
PCR amplifications containing the guinea pig genomic DNA probably reflects variation
is the absolute amount of starting material isolated from each section of the grid and the
degree of sample homogenization as well as the amplification efficiency and pipetting
errors discussed in the previous section. Figure 42 is representative of most amplification
profiles observed during testing involving guinea pig tissue.
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Figure 42. Amplification using modhARFI/Ri primers for unknowns.
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A series of 5 experiments were done consecutively, labeled A, B, C, D and E
(actual data can be seen in Appendix F). After the 150 Am tissue slices where placed in
the instrument, cut, transferred and homogenized, experiments A and B were isolated at
the same time, C and D together and E together with controls of guinea pig samples that
were not prepared using the sampling device. All experiments used the modhAR F2 and
RI primer set and the modified isolation protocol.
For the analysis of the collected data, an average of 12 wells was used and the CP
for each experiment was averaged and compared to the other four using analysis of
variance (ANOVA) for a repeated experiment. ANOVA is used to determine the
significance of the effects in a model by calculating how much of the variability in the
dependant variable can be explained by the effect in question. In these experiments, the
"effect" is testing different samples A, B, C etc with the hope that the dependant variable,
the initial concentrations of DNA per experiment are not affected by this effect. Using
StatView software for Repeat Measures ANOVA, the experiments could be compared
across all five, or within the groups used to isolate the DNA (an additional effect), as this
could contribute to systematic errors when comparing sets.
Interaction Bar Plot for Experiments
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Figure 43. Sample CP Mean for Each Experiment.
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Figure 43 shows the mean calculated for all the wells in each experiment. It is
interesting to observe that the averages were similar when the experiments were prepared
(performed consecutively on the same day as well as isolated) together. Experiments A,
B and E all have higher variances than C and D as well as higher means (see Table 5).
Table 5. Means Table for Experiments
Experiment Count Mean Std. Dev. Std. Error
A 12 33.008 4.702 1.357
B 12 34.131 4.971 1.435
C 12 30.106 0.953 0.275
D 12 29.353 1.731 0.5
E 12 32.306 3.098 0.894
Of the summary statistics, the one which best indicates the level of variability is
the P-value. This is the probability that the effect influences the behavior of the
dependant variable. In this case, the data generates a low P-value, p < 0.01, suggesting
that the different experiments do in fact vary significantly at a 95% confidence level.
Table 6. ANOVA Summary Table for Experiments.
DF Sum of Squares Mean Squares F-Value P-Value Lambda Power
Subject 11 119.595 10.872
Category for Experiments 4 192.015 48.004 3.883 0.009 15.533 0.871
Category for Expts - Subjects 44 543.917 12.362
Although this statistic is not encouraging, when accounting for the separate effect
of test grouping and isolations, it appears that this effect does have a significant effect on
the average well concentration of DNA as well as the variance of the data collected
within one set of tests carried out together.
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Analysis of the groupings A and B and C and D show that within a group, the
variability due to the "effect" within those experiments becomes negligible. Table 8
below shows that groupings exhibit very high p-values, p >> 0.05. These statistics
encourage the idea that the variability from test to test lies with the operator or device
operation and settings, rather than the instrument, or amplification process itself.
Table 7. Grouped Experiment Statistics
Grouping p-value
A B C D E 0.0087
A B 0.6269
C D 0.3201
A B E 0.6002
Actual yields for the five experiments averaged between a minimum 7 ng/pd and a
maximum 9.65 mg/pl. These yields were actually much better than the conservative
estimate (10% transfer efficiency, 2.67 jxg) that was calculated to be transferred. The
concentration transferred averaged 3 times the maximum expected concentration.
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Chapter 7 Conclusion
The instrument presented in this thesis was designed and fabricated for the
molecular profiling of frozen tissue samples. In particular, the AR as a marker for
prostate cancer tumors was targeted for amplification from the samples with the intention
of determining tumor boundaries. This first prototype and the series of experiments
performed have proven that the instrument does accomplish the task of cutting,
separating, transferring and homogenizing a frozen tissue sample so that nucleic acids
may be extracted. Testing also verified that the quantity, approximately 7.67 ng/pil per
well, of the isolated DNA from the samples was such that it exceeded the transfer
efficiency expectations and could easily be amplified using rt-PCR.
The quality of the DNA, although suspect at times, amplified the f-globin primer
segment across the entire range of dilution concentrations and was good enough to
repeatedly amplified segments of 152 bp lengths expected from the modhAR F2 and RI
primer set. These results bode well for the use of this device to identify the initial AR
concentrations in spatially distinct locations of a tissue sample, mapping this expression
as a marker for cancer tumors.
Further work in this area would focus on refining the cutting tool for better
resolution of tumor boundaries, improving the transfer mechanism to increase the amount
of tissue transferred successfully and to eliminate any operator or handling "effect" on
the set of experiments with respect to others. Another helpful addition would involve
incorporating a cooling system for the blade array and enclosing the tower to reduce heat
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transfer to the system. This is a necessity when dealing with more delicate material like
RNA, as keeping the tissue frozen becomes critical.
Another area that needs optimization is the rt-PCR process for the modhAR
primers. The primer sets used, while sufficient to find the required data, were difficult to
optimize and continued to exhibit non specific priming. The testing verified the difficulty
of obtaining a complete standard curve with these primers and the gels indicate that DNA
appeared to be intact as there were multiple instances of larger bp fragments being
amplified. An attempt was made to ascertain if there were differences between the
priming of human genomic DNA and the guinea pig genomic DNA, however, because of
non specific amplification, it was unclear that the DNA source caused any significant
differences.
This device, the process and others like it will revolutionize the diagnosis and
treatment of prostate cancer by providing more accurate information about tumor
boundaries quickly and efficiently, reducing the wait time to surgery. With further
refining it can become an in surgery instrument that provides real time profiling,
eliminating steps in the cancer treatment process.
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Appendix A: Tissue Sampling Protocol and Checklist
Prep:
O fill dry ice tray to cool cutting plate
0 determine the placement of sample on the cutting plate by aligning blades and
well plate. Note wells in use.
0 load buffer (vol based on thickness) into predetermined (based on tissue position)
well plate cells El 25ul of ATL 02.85 ul of Proteinase K
El dip blade array in glycerol. (use a paint brush for application)
0 let cutting block contact blades to cool them, add a pre-STEPI program for stage.
El set water bath to 550 for after mechanical homogenization T I I I
STEP 1:
Place tissue on cooled cutting plate.
STEP 2:
Advance stage with sample on compliant surface, upwards into blade array until cutting
occurs and force plateaus (force necessary; based on sample thickness)
STEP 3:
Lower stage (tissue still in array). And replace cutting platform with 384 well plate.
STEP 4:
Solenoid is triggered and agitating platform
version).
Start data collection.
STEP 5:
Voice coil drives the homogenization process
is lowered. (manual actuation in current
Amplitude (pp) Frequency (Hz) Duration
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Appendix B: DNeasy DNA Isolation Protocol
DNeasy Protocol for Animal Tissues
* Important notes before starting
* Before using the DNeasy Tissue Kit for the first time, please read "Technical
Information" on pages 9-16 of DNeasy Tissue Kit Handbook 05/2002.
* Buffers ATL and AL * may form precipitates upon storage. If a precipitate has formed in
either buffer, incubate the Buffer at 55'C until the precipitate has fully dissolved.
* Buffers AWl * and A W2t are supplied as concentrates. Before using for the first time,
add the appropriate amounts of ethanol (96-100%) to Buffers AWl and A W2 as
indicated on the bottles.
* Prepare a 55'C shaking water bath for use in step 2 and a 70 C water bath or heating
block for use in step 3.
* If using frozen material, equilibrate the sample to room temperature.
* To isolate DNA from fixed tissue, please refer to "Guidelines for preparation and lysis of
other starting material" (starting on page 25).
* All centrifugation steps are carried out at room temperature at >000 x g.
* Vortexing should be performed by pulse vortexing for 05-10 s.
* Optionally, RNase A may be used to digest RNA during the procedure. RNase A is not
provided in the DNeasy Tissue Kit (see "Copurification of RNA", page 12).
1. Cut up to 25 mg tissue (up to 10 mg spleen) into small pieces, place in a 1.5 ml
microcentrifuge tube, and add 180 tl Buffer ATL
Ensure the correct amount of starting material is used (see page 9). For tissues such as spleen
with a very high number of cells for a given mass of tissue, no more than 10 mg starting
material should be used.
It is advisable to cut the tissue into small pieces to enable more efficient lysis.
2. Add 20 Al proteinase K, mix by vortexing, and incubate at 55*C until the tissue is
completely lysed. Vortex occasionally during incubation to disperse the sample, or
place in a shaking water bath or on a rocking platform.
Lysis time varies depending on the type of tissue processed. Lysis is usually complete in 1-3
h. If it is more convenient, samples can be lysed overnight; this will not affect them
adversely. After incubation, the lysate may appear viscous but should not be gelatinous as it
may clog the DNeasy spin column. If the lysate appears very gelatinous, please see the
"Troubleshooting Guide" on page 30 for recommendations.
Optional: RNase treatment of the sample. Add 4 pl of RNase A (100 mg/ ml), mix by
vortexing, and incubate for 2 min at room temperature.
Transcriptionally active tissues such as liver and kidney contain high levels of RNA, which
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will copurify with genomic DNA. If RNA-free genomic DNA is required, carry out this
optional step. If residual RNA is not a concern, omit this step and continue with step 3.
3. Vortex for 15 s. Add 200 j1 Buffer AL to the sample, mix thoroughly by vortexing,
and incubate at 70*C for 10 min.
It is essential that the sample and Buffer AL are mixed immediately and thoroughly by
vortexing or pi petting to yield a homogeneous solution.
A white precipitate may form on addition of Buffer AL, which in most cases will dissolve
during the incubation at 70*C. The precipitate does not interfere with the DNeasy procedure.
Some tissue types (e.g., spleen, lung) may form a gelatinous lysate after addition of Buffer
AL. In this case, vigorously shaking or vortexing the preparation before addition of ethanol in
step 4 is recommended.
4. Add 200 g1 ethanol (96-100%) to the sample, and mix thoroughly by vortexing.
It is important that the sample, Buffer AL, and the ethanol are mixed thoroughly to
yield a homogeneous solution.
A white precipitate may form on addition of ethanol. It is essential to apply all of the
precipitate to the DNeasy spin column.
5. Pipet the mixture from step 4 into the DNeasy spin column placed in a 2 ml
collection tube (provided). Centrifuge at 6000 x g (8000 rpm) for 1 min. Discard
flow-through and collection tube.
6. Place the DNeasy spin column in a new 2 ml collection tube (provided), add 500 IA1
Buffer AWl, and centrifuge for 1 min at 6000 x g (8000 rpm). Discard flow-
through and collection tube.
7. Place the DNeasy spin column in a 2 ml collection tube (provided), add 500 A1
Buffer AW2, and centrifuge for 3 min at full speed to dry the DNeasy membrane.
Discard flow-through and collection tube.
This centrifugation step ensures that no residual ethanol is carried over during the following
elution. Discard flow-through and collection tube.
Following the centrifugation step, remove the DNeasy spin column carefully so that the
column does not come into contact with the How-through, since this will result in carryover
of ethanol. (If carryover of ethanol occurs, empty the collection tube and reuse it in another
centrifugation step for 1 min at full speed.)
8. Place the DNeasy spin column in a clean 1.5 ml or 2 ml microcentrifuge tube (not
provided), and pipet 200 Al Buffer AE directly onto the DNeasy membrane.
Incubate at room temperature for 1 min, and then centrifuge for 1 min at 6000 x g
(8000 rpm) to elute.
Elution with 100 pi (instead of 200 pi) increases the final DNA concentration in the eluate,
but also decreases the overall DNA yield (see Figure 2, page 13).
9. Repeat elution once as described in step 8.
A new microcentrifuge tube can be used for the second elution step to prevent dilution of the
first eluate. Alternatively, to combine the eluates, the microcentrifuge tube from step 8 can be
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reused for the second elution step.
Note: More than 200 pl should not be eluted into a 1.5 ml microcentrifuge tube because the
DNeasy mini column will come into contact with the eluate.
The DNeasy isolation protocol was modified in the following ways:
i. Step 1. was eliminated.
ii. Volumes were scaled to fit the well volume of the well plate.
200 Al reduced to 50 zl
500 pl reduced to 100 Il
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Appendix C: Real Time PCR protocol
16may05
M27430 Human androgen receptor gene, exon 8/ncbi genelD #HGNC:644 - display gene table:
Intron 7 - 701bp - 178954...179654
Exon 8 - 156bp - 179655...179810
Act->"ct
gtaagcaaac
atgcttctct
agtgtggtcc
gatattgtga
tgcagcagat
gagtcatgtt
tgtgtgtgtc
cacaagctgg
gatggagggt
agagtctggc
aggaagaaaa
aaggggtgga
gaattctcta
catgtgagtt
agagagagag
agaagtcttg
ccctcagtga ctccatggag
acacacacac acacacgacc
gctttatcag
accacctgtt
tgtggtgaag
ggagttgaga
ggcagacaaa
tgtctgtctg
agagagagag
agtcagagag
accatttctt
tcatggggga
ggagaacagc
gggaggtgct
aaaagaacac
acagagcagt
acagacctgg
tgtgtgtgtg
agagatggag
cttacaatgg
tctctctctc
ggaccaagga
ctgatagagc
tccattcccc
gggtcacagt
tgggactcag
atgtttttcc
tgtgtgtgtg
tgcggaggct
tataagacat
tcgctgtctc
agtacgggga
caatgataat
tctggctttg
gtcccagctg
ggaagggact
cctcttcttt
tgtgtgtgtg
tgggtgagag
ctcttgggag
tctctaacac
agggggagga
aacaaaaggc tgaaagacca aaaatcagag gttggggaag
mod hAR F2-> CCtC
mod hAR Fl-> cacctc
aggctagcag aggccacctc
cttgtcaacc
cttgtcaacc
cttgtcaacc
agttc cttt
tggcagagat
ta
atttccacac
L L
C
ctgttt
ctgt
ctgtttttct
tgacctgcta
catctctgtg
gtagagacac
agagacac
ccctcttatt
atcaagtcac
caagtgccca
gttccctaca
acatggtgag
agatcctttc
gattgcgaga
cgtggacttt
tgggaaagtc
gagctgcatc
ccggaaatga
aagcccatct
gttcacgg <-mod hAR R1
gttcacgggt t <-mod hAR R2
ccagtga t
primers/probes used for experimental analysis of tissue extracts - 5'-cctc...-3' etc
common primers designed by roche for hAR intronexon8 - 5'-cttg....-3'
5-aatgct...-3'
gives 204bp PCR product
BASIC setup used to amplify DNA extracted from tissue sections isolated was as follows -
Using the SYBR Green Fast Start MasterPLUS Kit
Thaw 1 vial of reaction mix (vial 1 b, green cap)
Briefly centrifuge 1 vial enzyme (vial 1a, white cap) and thawed reaction mix (1b)
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Pipette 14ul vial 1a (white) into vial lb (green)
Mix by pipetting up and down
Re-label vial 1 b
1. 110bp f-globin fragment -
Final conc
H20 12uL x672
fi-globin primer mix 5uM each 2uL 12
SYBRGLCFSDNAM+1x 4uL 24
18uL 108
Aliquot 18uL into individual capillaries
Set up H20 controls before handling any genomic DNA
Add 2uL appropriate genomic DNA to remaining capillaries - undiluted
15ng/uL
1:10 (in H20) 1.5ng/uL
1:100 (in H20) 150pg/uL
1:1000 (in H20) 15pg/uL
1:10000 (in H20)
1.5pg/uL
+ H20 blk
2. +ve control - 154bp fragment
H20 12uLx6 72uL
modhARF1 1.0uL 10uM 6.OuL
modhARR1 1.OuL 10uM 6.OuL
SYBR G LCFS DNA M+4.OuL 24.OuL
18uL 108
+H20 control
3. unknowns - 16samples @ 2.6ng/uL
Set up reactions containing primers that have been in use and primers that have been
made from 20uM stocks of modhARF1/R1 and modhARF2/R2 using new tube of pcr-
grade H20
Final conc
H20 12.OuL x18= 216
modhARF1 (old or new) 0.5uM 1.OuL 10uM 18
modhARRI (old or new)0.5uM 1.OuL 10uM 18
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LCfsSYBR G 4.OuL 7
18.OuL 32
Aliquot 18uL into individual capillaries
set up H20 controls before handling any genomic DNA
add 2uL appropriate genomic DNA to remaining capillaries
cap tubes, centrifuge at 800rpm for 0.5min
load LC and cycle as follows - preincubation 5min @95
amplification 95C for 10
Melt
Cool
2
4/18 = 18
C
s
52C for 1Os
72C for 1Os; 20C/s; single
Repeat 45x
95C for Os
50C for 15s
95C for Os; 0.1C/s; continuous
40C for 30s
USING SYBR G LCFS DNA Master without MgC2
(July 16th)
Thaw 1 vial of reaction mix (vial 1 b, green cap) (shield from light)
Briefly centrifuge 1 vial enzyme (vial 1 a, white cap) and thawed reaction mix (1 b)
Pipette 1Oul vial 1a (white) into vial 1b (green)
Mix by pipetting up and down ( DO NOT vortex)
Re-label vial 1 b
4. 11 Obp -globin fragment -
Final conc
H20
P-globin primer mix
SYBR G LCFS
25mM MgC2
SuM each
1x
4mM
11.6uL x12 139.2
2uL 24
2uL 24
2.4uL 28.8
18uL 216
Aliquot 18uL into individual capillaries
Set up H20 controls before handling any genomic DNA
Add 2uL appropriate genomic DNA to remaining capillaries -
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undiluted
1:10 (in H20)
15ng/uL
1.5ng/uL
1:100 (in H20)
1:1000 (in H20)
1:10000 (in H20)
150pg/uL
15pg/uL
1.5pg/uL
+ H20 blk
5. 6 dilutions ( 5 dilutions + blk) & up to 8 modified isolation GP dna samples
Set up reactions containing primers that have been made from 40uM stocks of modhARF2/R1 using new
tube of pcr-grade H20
Final conc
H20
modhARF2 (new)
modhARR1 (old)
LCfsSYBR G
25mM MgCl2
0.5uM
0.5uM
4mM
11.6uL x20 232
1.OuL 10uM 20
1.OuL 10uM 20
2.OuL 40
2.4uL 48
18.OuL 360/20 = 18
Aliquot 18uL into individual capillaries
set up H20 controls before handling any genomic DNA
add 2uL appropriate genomic DNA to remaining capillaries
cap tubes, centrifuge at 800 rpm for 0.5min
load LC and cycle as follows - preincubation
amplification
Melt
Cool
insert the capillaries into the instrument and run program - pre-incub
amplifica
5min @95C
95C for 1Os
52C for 1Os
72C for 1Os; 20C/s; single
Repeat 55x
95C for Os
50C for 15s
95C for Os; 0.1C/s; continuous
40C for 30s
ation 95C, 10 min, 20C/s,
tion 95C, 10s, 20C/s, no
no acquisition
acquisition
55C, 10s, 20C/s, no acquisition
72C, 10s (bp/25), 20C/s, single
Repeat cycle 45x
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Melt
Cooling
95C, Os, 20C/s, no acquisition
55C, 30s, 20C/s, no acquisition
95C, Os, 0.1C/s, continuous
40C, 30s, 20C/s, no acquisition
Non-Quantitative PCR
final
conc amtI25ul amt220ul
1Ox PCR buffer Ix 2.5 x4 10 *2 20
primer 1-forward 0.2uM 0.5 2
primer 2-reverse 0.2uM 0.5 2
0.2mM
25mM 4dNTP each 0.2 0.8 *2 1.6
TAQ DNA polymerase
(5UIul) 2.5U 0.125 0.5 *2 1
MgC12 0.15mM 2.5 10 *2 20
total 6.325 21.3 *2 42.6
H2o 18.175 72.7 *2 145.4
24.5 94 188
1_ 23.5 94
DNA 0.5
86
undiluted
Appendix D: Matlab for model fitting
>> fresult = fit(time,force,'sin','start',[1.3 1000 0])
fresult =
General model Sini:
fresult(x) = al*sin(bl*x+cl)
Coefficients (with 95% confidence bounds):
al = 1.381 (1.381, 1.382)
bl = 1000 (1000,1000)
cl = -39.53 (-39.54, -39.51)
%% this is the function used to plot graph: y8 = 1.381*sin(1000*x+39.87);
>> fresult = fit(time,acc,'sini','start',[.004 1000 0])
fresult =
General model Sin1:
fresult(x) = al*sin(bl*x+cl)
Coefficients (with 95% confidence bounds):
al = 0.004337 (0.004181, 0.004493)
bl = 1000 (999.8, 1000)
cl = 1.649 (0.59, 2.708)
>> fresult = fit(time,acc,'sinl','start',[.003 1000 0])
fresult =
General model Sin1:
fresult(x) = al*sin(bl*x+cl)
Coefficients (with 95% confidence bounds):
al = 0.004337 (0.004181, 0.004493)
bl = 1000 (999.8, 1000)
cl = 1.649 (0.59, 2.708)
>> fresult = fit(time,acc,'sinl','start',[.005 1000 0])
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fresult =
General model Sin1:
fresult(x)= al*sin(bl*x+cl)
Coefficients (with 95% confidence bounds):
al = 0.004337 (0.004181, 0.004493)
bi = 1000 (999.8, 1000)
cl = -4.634 (-5.693, -3.575)
Average = -0.00155
y2 = -0.0019 +.00434*sin(1000*x-0.6);
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Appendix E: Matlab script for image processing
%The original script written by Bryan Crane and was edited by Sasha Manoosingh.
%Picture must be converted to a greyscale tif image first.
clear
fl =imread('gel4.tif);
figure
image(fl)
imagesc(fl,[0,255]);
fl=double(fl);
figure
imagesc(fl,[0,255]);
filteredfl=medfilt2(fl);
figure
imagesc(filtered fl,[0,255]);
title('filtered')
figure
imagesc(filtered fl,[10,180]);
title('filtered')
figure
colorbar;
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Appendix F: ANOVA Repeated Experiment
Table 8. Statistical Summary of Experimental Data
Experimerts
A B C D E
Type: Real Real Real Real Real
Source: User Entered User Entered User Entered User Ertered User Entered
Class: Continuous Continuous Continuous Continuous Continuous
Format: Free Format Fi... Free Format Fi... Free Format Fi.. Free Format Fi... Free Format Fi...
k Dec.Places: 2 2 2 2 2
Mean- 33.01 34.13 30.11 29.35 32.31
Std. Deviatior: 4.70 4.97 .95 1.73 3.10
Std. Error: 1.36 1.43 .28 .50 .89
Variance 22.11 24.71 .91 3.00 9.60
Coeff. of Variation: .14 .15 .03 .06 .10
Minimum' 26.91 25.63 28.43 24.72 26.07
Maximum: 40.67 43.78 31.71 32.31 37.20
Rar: 13.76 18.15 3.28 7.59 11.13
Count: 12 12 12 12 12
tissing Cels: 0 0 0 0 0
Sum: 396.09 409.57 361.27 352.24 387.67
Sum of s: 13317.10 14250.78 10886.32 10372.37 12629.60
1 3.5 31.9 28.43 32.31 31.46
2 40.67 2.63 28.80 29.56 30.94
3 27.71 34.33 31.71 28.46 31.85
4 32.77 32.79 29.52 29.30 33.85
51 38.56 35.91 30.28| 28.981 35.83
6 38.23| 38.47 30.41 29.96 29.49
71i 27.26| 40.34 |31.45| 24.72| 31.87
8 31.87 43.78 30.21 29.75 37.20
9 31.71 32.93 29.60 30.06 26.07
10 26.91 32.17 29.87 29.95 29.86
11 29.79 32.87 30.51 29.96 35.02
12 33.87 28.46 30.48 29.23 34.23
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